Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Arcus Biosciences (RCUS) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Arcus Biosciences (RCUS) over the last 6 years, with Dec 2024 value amounting to -$3.14.

  • Arcus Biosciences' EPS (Weighted Average and Diluted) fell 27.00% to -$1.27 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.44, marking a year-over-year decrease of 40.95%. This contributed to the annual value of -$3.14 for FY2024, which is 24.34% up from last year.
  • Latest data reveals that Arcus Biosciences reported EPS (Weighted Average and Diluted) of -$3.14 as of FY2024, which was up 24.34% from -$4.15 recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' EPS (Weighted Average and Diluted) registered a high of $0.71 during FY2021, and its lowest value of -$4.15 during FY2023.
  • For the 3-year period, Arcus Biosciences' EPS (Weighted Average and Diluted) averaged around -$3.67, with its median value being -$3.71 (2022).
  • As far as peak fluctuations go, Arcus Biosciences' EPS (Weighted Average and Diluted) surged by 131.70% in 2021, and later crashed by 622.54% in 2022.
  • Yearly analysis of 5 years shows Arcus Biosciences' EPS (Weighted Average and Diluted) stood at -$2.24 in 2020, then skyrocketed by 131.70% to $0.71 in 2021, then slumped by 622.54% to -$3.71 in 2022, then fell by 11.86% to -$4.15 in 2023, then increased by 24.34% to -$3.14 in 2024.